Lisa Licitra
University of Milan
CancerRadiologySurgeryPathologyOncologyClinical endpointHead and neck cancerInduction chemotherapyChemotherapyHead and neck squamous-cell carcinomaCarcinomaCisplatinCetuximabNivolumabPopulationPhases of clinical researchCancer researchRadiation therapyClinical trialMedicine
563Publications
68H-index
15.2kCitations
Publications 561
Newest
#1Valentina D. A. Corino (Polytechnic University of Milan)H-Index: 17
#2Marco Bologna (Polytechnic University of Milan)H-Index: 6
Last. Paolo Bossi (University of Brescia)H-Index: 37
view all 20 authors...
Baseline clinical prognostic factors for recurrent and/or metastatic (RM) head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy are lacking. CT-based radiomics may provide additional prognostic information. A total of 85 patients with RM-HNSCC were enrolled for this study. For each tumor, radiomic features were extracted from the segmentation of the largest tumor mass. A pipeline including different feature selection steps was used to train a radiomic signature prognostic for ...
Source
#1Salvatore AlfieriH-Index: 17
Last. Lisa Licitra (University of Milan)H-Index: 68
view all 29 authors...
To identify and validate baseline magnetic resonance imaging (b-MRI) radiomic features (RFs) as predictors of disease outcomes in effectively cured head and neck squamous cell carcinoma (HNSCC) pat...
Source
#1Alexander J. Stratigos (UoA: National and Kapodistrian University of Athens)H-Index: 45
#2Aleksandar Sekulic (Mayo Clinic)H-Index: 25
Last. Matthew G. Fury (Regeneron)H-Index: 34
view all 38 authors...
Summary Background Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. Cemiplimab, a PD-1 antibody, is approved for treatment of advanced cutaneous squamous cell carcinoma and has shown clinical activity as monotherapy in first-line non-small-cell lung cancer. Here, we present the primary analysis data of cemiplimab in patients with locally advanced basal cell carcinoma after HHI therapy. Meth...
1 CitationsSource
#1Lori J. Wirth (Harvard University)H-Index: 54
#2Marcia S. Brose (UPenn: University of Pennsylvania)H-Index: 45
Last. Maria E. Cabanillas (University of Texas MD Anderson Cancer Center)H-Index: 41
view all 18 authors...
PURPOSE Anaplastic thyroid cancer (ATC), an aggressive malignancy, is associated with a poor prognosis and an unmet need for effective treatment, especially for patients without BRAF mutations or NTRK or RET fusions. Lenvatinib is US Food and Drug Administration-approved for radioiodine-refractory differentiated thyroid cancer and has previously demonstrated activity in a small study of patients with ATC (n = 17). We aimed to further evaluate lenvatinib in ATC. METHODS This open-label, multicent...
Source
#1Luigi LoriniH-Index: 2
#2Marco MerlanoH-Index: 27
Last. Paolo BossiH-Index: 37
view all 5 authors...
Source
#1Jessica L. Geiger (Cleveland Clinic)H-Index: 11
#2Nofisat Ismaila (American Society of Clinical Oncology)H-Index: 17
Last. Patrick K. Ha (UCSF: University of California, San Francisco)H-Index: 41
view all 17 authors...
PURPOSETo provide evidence-based recommendations for practicing physicians and other healthcare providers on the management of salivary gland malignancy.METHODSASCO convened an Expert Panel of medi...
Source
#1Claire Petit (Université Paris-Saclay)H-Index: 1
#2Benjamin Lacas (Université Paris-Saclay)H-Index: 10
Last. L.P. Zhong (SJTU: Shanghai Jiao Tong University)
view all 169 authors...
Summary Background Randomised, controlled trials and meta-analyses have shown the survival benefit of concomitant chemoradiotherapy or hyperfractionated radiotherapy in the treatment of locally advanced head and neck cancer. However, the relative efficacy of these treatments is unknown. We aimed to determine whether one treatment was superior to the other. Methods We did a frequentist network meta-analysis based on individual patient data of meta-analyses evaluating the role of chemotherapy (Met...
Source
#1Stefano Cavalieri (University of Milan)H-Index: 8
#2Elena Colombo (University of Milan)H-Index: 13
Last. Lisa Licitra (University of Milan)H-Index: 68
view all 15 authors...
OBJECTIVE: To capture and monitor flu-like symptoms in relation to the clinical characteristics and the oncologic treatment of a large head and neck cancer (HNC) patient cohort during the Coronavirus disease 2019 (COVID-19) pandemic. METHODS: Patients were monitored through by 2 rounds of interviews. Clinical characteristics of patients with no symptoms (group 0) and of those reporting ⩾1 (group A), ⩾3 (group B), or ⩾5 symptoms (group C) were analyzed. Patients with ⩾1 symptom at both in...
Source
#1Daria Maria Filippini (UNIBO: University of Bologna)H-Index: 2
#2Milo Gatti (UNIBO: University of Bologna)H-Index: 6
Last. Lisa Licitra (University of Milan)H-Index: 68
view all 8 authors...
Although immune checkpoint inhibitors (ICIs) are associated with different immune-related adverse events (irAEs), the potential effect on the skeleton is poorly defined albeit biologically plausible and assessable through pharmacovigilance. We described a case series of patients experiencing skeletal fractures while on ICIs at the National Cancer Institute of Milan. To better characterize the clinical features of skeletal irAEs reported with ICIs, we queried the FDA Adverse Reporting System (FAE...
Source
#1Stefano Cavalieri (University of Milan)H-Index: 8
#2Lisa Licitra (University of Milan)H-Index: 68
Source